TY - JOUR
T1 - The EUS molecular evaluation of pancreatic cancer
T2 - A prospective multicenter cohort trial
AU - Masoumi-Moghaddam, Samar
AU - Lundy, Joanne
AU - Gao, Hugh
AU - Rathi, Vivek
AU - Swan, Michael
AU - Desmond, Christopher
AU - Bhutani, Manoop
AU - Southey, Melissa
AU - Vaughan, Rhys
AU - Varma, Poornima
AU - Tagkalidis, Peter
AU - Holt, Bronte
AU - Pilgrim, Charles C.
AU - Segelov, Eva
AU - Lee, Belinda
AU - Harris, Marion
AU - Strickland, Andrew
AU - Frentzas, Sophia
AU - Zalcberg, John
AU - Jenkins, Brendan
AU - Croagh, Daniel
N1 - Publisher Copyright:
© 2021 Spring Media. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Background and Objectives: Patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (A-PDAC) are not candidates for surgical resection and are often offered palliative chemotherapy. The ready availability of a safe and effective tumor sampling technique to provide material for both diagnosis and comprehensive genetic profiling is critical for informing precision medicine in A-PDAC, thus potentially increasing survival. The aim of this study is to examine the feasibility and benefits of routine comprehensive genomic profiling (CGP) of A-PDAC using EUS-FNA material. Methods: This is a prospective cohort study to test the clinical utility of fresh frozen or archival EUS-FNA samples in providing genetic material for CGP. The results of the CGP will be reviewed at a molecular tumor board. The proportion of participants that have a change in their treatment recommendations based on their individual genomic profiling will be assessed. Correlations between CGP and stage, prognosis, response to treatment and overall survival will also be investigated. This study will open to recruitment in 2020, with a target accrual of 150 A-PDAC patients within 36 months, with a 2-year follow-up. It is expected that the majority of participants will be those who have already consented for their tissue to be biobanked in the Victorian Pancreatic Cancer Biobank at the time of diagnostic EUS-FNA. Patients without archival or biobanked material that is suitable for CGP may be offered a EUS-FNA procedure for the purposes of obtaining fresh frozen material. Discussion: This trial is expected to provide crucial data regarding the feasibility of routine CGP of A-PDAC using EUS-FNA material. It will also provide important information about the impact of this methodology on patients' survival.
AB - Background and Objectives: Patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (A-PDAC) are not candidates for surgical resection and are often offered palliative chemotherapy. The ready availability of a safe and effective tumor sampling technique to provide material for both diagnosis and comprehensive genetic profiling is critical for informing precision medicine in A-PDAC, thus potentially increasing survival. The aim of this study is to examine the feasibility and benefits of routine comprehensive genomic profiling (CGP) of A-PDAC using EUS-FNA material. Methods: This is a prospective cohort study to test the clinical utility of fresh frozen or archival EUS-FNA samples in providing genetic material for CGP. The results of the CGP will be reviewed at a molecular tumor board. The proportion of participants that have a change in their treatment recommendations based on their individual genomic profiling will be assessed. Correlations between CGP and stage, prognosis, response to treatment and overall survival will also be investigated. This study will open to recruitment in 2020, with a target accrual of 150 A-PDAC patients within 36 months, with a 2-year follow-up. It is expected that the majority of participants will be those who have already consented for their tissue to be biobanked in the Victorian Pancreatic Cancer Biobank at the time of diagnostic EUS-FNA. Patients without archival or biobanked material that is suitable for CGP may be offered a EUS-FNA procedure for the purposes of obtaining fresh frozen material. Discussion: This trial is expected to provide crucial data regarding the feasibility of routine CGP of A-PDAC using EUS-FNA material. It will also provide important information about the impact of this methodology on patients' survival.
KW - EUS-FNA
KW - archival tissue
KW - comprehensive genomic profiling
KW - fresh frozen tissue
KW - pancreatic duct adenocarcinoma
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85118299002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118299002&partnerID=8YFLogxK
U2 - 10.4103/EUS-D-20-00230
DO - 10.4103/EUS-D-20-00230
M3 - Review article
C2 - 34558422
AN - SCOPUS:85118299002
SN - 2303-9027
VL - 10
SP - 335
EP - 343
JO - Endoscopic Ultrasound
JF - Endoscopic Ultrasound
IS - 5
ER -